Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?

Natalie R. Boonzaier, Sara G.M. Piccirillo, Colin Watts, Stephen J. Price

Research output: Contribution to journalReview article

Abstract

Glioblastoma demonstrates imaging features of intratumor heterogeneity that result from underlying heterogeneous biological properties. This stems from variations in cellular behavior that result from genetic mutations that either drive, or are driven by, heterogeneous microenvironment conditions. Among all imaging methods available, only T1-weighted contrast-enhancing and T2-weighted fluid-attenuated inversion recovery are used in standard clinical glioblastoma assessment and monitoring. Advanced imaging modalities are still considered emerging techniques as appropriate end points and robust methodologies are missing from clinical trials. Discovering how these images specifically relate to the underlying tumor biology may aid in improving quality of clinical trials and understanding the factors involved in regional responses to treatment, including variable drug uptake and effect of radiotherapy. Upon validation and standardization of emerging MR techniques, providing information based on the underlying tumor biology, these images may allow for clinical decision-making that is tailored to an individual's response to treatment.

Original languageEnglish (US)
Pages (from-to)399-410
Number of pages12
JournalCNS oncology
Volume4
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

Multimodal Imaging
Glioblastoma
Clinical Trials
Neoplasms
Radiotherapy
Mutation
Therapeutics
Pharmaceutical Preparations

Keywords

  • advanced imaging
  • glioblastoma
  • intratumor heterogeneity
  • subregional assessment
  • underlying biology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Assessing and monitoring intratumor heterogeneity in glioblastoma : how far has multimodal imaging come? / Boonzaier, Natalie R.; Piccirillo, Sara G.M.; Watts, Colin; Price, Stephen J.

In: CNS oncology, Vol. 4, No. 6, 01.01.2015, p. 399-410.

Research output: Contribution to journalReview article

Boonzaier, Natalie R. ; Piccirillo, Sara G.M. ; Watts, Colin ; Price, Stephen J. / Assessing and monitoring intratumor heterogeneity in glioblastoma : how far has multimodal imaging come?. In: CNS oncology. 2015 ; Vol. 4, No. 6. pp. 399-410.
@article{780d1e102c734249b36d318d6286c283,
title = "Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?",
abstract = "Glioblastoma demonstrates imaging features of intratumor heterogeneity that result from underlying heterogeneous biological properties. This stems from variations in cellular behavior that result from genetic mutations that either drive, or are driven by, heterogeneous microenvironment conditions. Among all imaging methods available, only T1-weighted contrast-enhancing and T2-weighted fluid-attenuated inversion recovery are used in standard clinical glioblastoma assessment and monitoring. Advanced imaging modalities are still considered emerging techniques as appropriate end points and robust methodologies are missing from clinical trials. Discovering how these images specifically relate to the underlying tumor biology may aid in improving quality of clinical trials and understanding the factors involved in regional responses to treatment, including variable drug uptake and effect of radiotherapy. Upon validation and standardization of emerging MR techniques, providing information based on the underlying tumor biology, these images may allow for clinical decision-making that is tailored to an individual's response to treatment.",
keywords = "advanced imaging, glioblastoma, intratumor heterogeneity, subregional assessment, underlying biology",
author = "Boonzaier, {Natalie R.} and Piccirillo, {Sara G.M.} and Colin Watts and Price, {Stephen J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.2217/cns.15.20",
language = "English (US)",
volume = "4",
pages = "399--410",
journal = "CNS oncology",
issn = "2045-0915",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Assessing and monitoring intratumor heterogeneity in glioblastoma

T2 - how far has multimodal imaging come?

AU - Boonzaier, Natalie R.

AU - Piccirillo, Sara G.M.

AU - Watts, Colin

AU - Price, Stephen J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Glioblastoma demonstrates imaging features of intratumor heterogeneity that result from underlying heterogeneous biological properties. This stems from variations in cellular behavior that result from genetic mutations that either drive, or are driven by, heterogeneous microenvironment conditions. Among all imaging methods available, only T1-weighted contrast-enhancing and T2-weighted fluid-attenuated inversion recovery are used in standard clinical glioblastoma assessment and monitoring. Advanced imaging modalities are still considered emerging techniques as appropriate end points and robust methodologies are missing from clinical trials. Discovering how these images specifically relate to the underlying tumor biology may aid in improving quality of clinical trials and understanding the factors involved in regional responses to treatment, including variable drug uptake and effect of radiotherapy. Upon validation and standardization of emerging MR techniques, providing information based on the underlying tumor biology, these images may allow for clinical decision-making that is tailored to an individual's response to treatment.

AB - Glioblastoma demonstrates imaging features of intratumor heterogeneity that result from underlying heterogeneous biological properties. This stems from variations in cellular behavior that result from genetic mutations that either drive, or are driven by, heterogeneous microenvironment conditions. Among all imaging methods available, only T1-weighted contrast-enhancing and T2-weighted fluid-attenuated inversion recovery are used in standard clinical glioblastoma assessment and monitoring. Advanced imaging modalities are still considered emerging techniques as appropriate end points and robust methodologies are missing from clinical trials. Discovering how these images specifically relate to the underlying tumor biology may aid in improving quality of clinical trials and understanding the factors involved in regional responses to treatment, including variable drug uptake and effect of radiotherapy. Upon validation and standardization of emerging MR techniques, providing information based on the underlying tumor biology, these images may allow for clinical decision-making that is tailored to an individual's response to treatment.

KW - advanced imaging

KW - glioblastoma

KW - intratumor heterogeneity

KW - subregional assessment

KW - underlying biology

UR - http://www.scopus.com/inward/record.url?scp=84983086737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983086737&partnerID=8YFLogxK

U2 - 10.2217/cns.15.20

DO - 10.2217/cns.15.20

M3 - Review article

C2 - 26497327

VL - 4

SP - 399

EP - 410

JO - CNS oncology

JF - CNS oncology

SN - 2045-0915

IS - 6

ER -